17:20 , Dec 16, 2016 |  BC Week In Review  |  Company News

Alnylam, Sanofi deal

Alnylam said Sanofi’s Sanofi Genzyme unit declined to exercise an option to co-develop and co-commercialize ALN-CC5 in territories outside of the U.S., Canada and Western Europe under a 2014 deal to develop and commercialize Alnylam's...
07:00 , Oct 10, 2016 |  BioCentury  |  Finance

Program or platform?

The slashing of $3.6 billion from Alnylam Pharmaceuticals Inc.'s market cap in a little more than a week suggests the markets are not comfortable with the company's argument that problems from two dropped programs will...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

ALN-CC5: Phase I/II ongoing

Alnylam said it will narrow its development program for ALN-CC5 to target poor responders to Soliris eculizumab and PNH patients who require Soliris sparing. The company was developing ALN-CC5 for a broader population of...
01:42 , May 4, 2016 |  BC Extra  |  Company News

Alnylam tumbles on ALN-CC5 update

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell $7.98 (12%) to $60.81 on Tuesday after reporting that it will narrow its development program for paroxysmal nocturnal hemoglobinuria (PNH) therapy ALN-CC5 to target poor responders to Soliris eculizumab from...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

ALN-CC5: Additional Phase I/II data

Data from 32 healthy volunteers in the double-blind first and second parts of a 3-part, U.K. Phase I/II trial showed that single and multiple subcutaneous doses of ALN-CC5 reduced mean maximum serum C5 levels by...
02:29 , Dec 11, 2015 |  BC Extra  |  Company News

Alnylam provides pipeline update

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it expects 10 "major clinical data readouts" next year and expects to have data from its first Phase III trial, a study of amyloidosis candidate patisiran ( ALN-TTR02), by YE17....
02:33 , Dec 8, 2015 |  BC Extra  |  Clinical News

Alnylam reports hemophilia, PNH interim data

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell $11.24 (10%) to $97.72 on Monday after it reported interim data from a Phase I study of fitusiran ( ALN-AT3) to treat hemophilia A and B and a Phase I/II...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

ALN-CC5: Phase I/II data

Data from 12 healthy volunteers in the double-blind, dose-escalation part A of a 3-part, U.K. Phase I/II trial showed that single doses of 50-400 mg subcutaneous ALN-CC5 were safe with no serious adverse events, treatment...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

ALN-CC5: Phase I/II started

Alnylam began a U.K. Phase I/II trial of subcutaneous ALN-CC5 in about 68 healthy volunteers and patients. The double-blind, placebo-controlled parts will evaluate single and multiple ascending doses in up to 60 volunteers. An open-label...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches...